Log in
Enquire now
‌

US Patent 10421747 Quinoxaline derivatives useful as FGFR kinase modulators

Patent 10421747 was granted and assigned to Astex Therapeutics Limited on September, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
Current Assignee
‌
Astex Therapeutics Limited
Date Filed
December 28, 2017
Date of Patent
September 24, 2019
Patent Applicant
‌
Astex Therapeutics Limited
Patent Application Number
15856998
Patent Citations
‌
US Patent 10052320 Substituted quinoxalines as FGFR kinase inhibitors
0
‌
US Patent 10039759 Quinolines as FGFR kinase modulators
‌
US Patent 10045982 Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors
‌
US Patent 10085982 Combinations
Patent Citations Received
‌
US Patent 11918576 Combination of an FGFR inhibitor and a CMET inhibitor
0
‌
US Patent 10716787 Combinations
0
‌
US Patent 10736900 Combinations of an FGFR inhibitor and an IGF1R inhibitor
‌
US Patent 10898482 Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
0
‌
US Patent 11684620 Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
0
Patent Inventor Names
Wim Vermeulen
0
Filip Albert Celine Cuyckens
0
Russell Mark Jones
0
Steven Anna Hostyn
0
Diego Fernando Domenico Broggini
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10421747
Patent Primary Examiner
‌
Venkataraman Balasubramanian

Find more entities like US Patent 10421747 Quinoxaline derivatives useful as FGFR kinase modulators

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.